Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
889
datasets available to search
ShareScore release 0.9.0
Dataset results
889 results for “fatty liver”
Dataset of B-mode fatty liver ultrasound images
<p>The dataset used and described in: M. Byra, G. Styczynski, C. Szmigielski, P. Kalinowski. Ł. Michałowski4. R. Paluszkiewicz. B. Ziarkiewicz-Wróblewska, K. Zieniewicz. P. Sobieraj, A. Nowicki. Transfer learning with deep convolutional neural network for liver steatosis assessment in ultrasound images. International Journal of Computer Assisted Radiology and Surgery, 2018. DOI: 10.1007/s11548-018-1843-2. </p> <p>Please refer to the above work if you use the dataset in your research. </p> <p>Contact:<br> Michal Byra<br> Department of Ultrasound<br> Institute of Fundamental Technological Research<br> Polish Academy of Sciences, Warsaw, Poland<br> mbyra@ippt.pan.pl<br> byra.michal@gmail.com</p>
Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure. Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.
<p>Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure.</p> <p>Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.</p>
Metadata of the study HMGCR activity is essential for mitochondrial β-oxidation of fatty acids to prevent lethal accumulation of long-chain acylcarnitines in the mouse liver
<p>Metadata of the study "HMGCR activity is essential for mitochondrial β-oxidation of fatty acids to prevent lethal accumulation of long-chain acylcarnitines in the mouse liver" published in Br J Pharmacol 2024. Apr 19. doi: 10.1111/bph.16363.</p>
Metabolomics of pediatric fatty liver disease
<p>Fecal and plasma metabolite profiles of non-alcoholic fatty liver disease (NAFLD) in a pediatric cohort</p>
VISION Invited lecture - Bariatric surgery and non-alcoholic fatty liver disease
<p>Recording and presentation of the invited lecture that took place online on 16 June 2021 - <strong>Pantelis Antonakis, MD, PhD - Bariatric surgery and non-alcoholic fatty liver disease.</strong></p> <p>Bariatric surgery is a documented solution for morbid obesity. Additionally to excess weight loss, significant improvement in comorbidities is an established benefit after bariatric operations. In recent years, non-alcoholic fatty liver disease (NAFLD) has emerged as one of these comorbidities. Herein we will review the data supporting the positive effect of bariatric surgery in patients with NAFLD.</p>
Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in human and animal models of non-alcoholic fatty liver disease
<p>Data sets used for the article entitled: "Accumulation of dihydrosphingolipids and neutral lipids is related to steatosis and fibrosis damage in human and animal models of non-alcoholic fatty liver disease"</p> <p>- Patient data: DATA Patients JLR.xlsx</p> <p>- Mouse data: DATA Mice.xlsx</p>
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
ClinicalTrials.gov study NCT03205150. IPD Sharing: YES. Countries: 8. Publications: 1.
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER St
ClinicalTrials.gov study NCT04216589. IPD Sharing: YES. Countries: 2. Publications: 2.
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
ClinicalTrials.gov study NCT04147195. IPD Sharing: YES. Countries: 3. Publications: 1.
Raw data related to: Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD)
<p><strong>Abstract</strong></p> <p>Fatty liver disease is a serious complication of childhood obesity. Calorie-restricted regimen (RCR) is one of the e ective therapy for this condition. Aim of the study was to evaluate the effect of lycopene-rich tomato sauce with oregano and basil extracts in obese children with fatty liver on RCR. 61 obese children with fatty liver were enrolled, 52 completed the study. A randomized cross over clinical trial was performed. Participants were assigned to RCR alone or with a supplement of lycopene-rich tomato juice for 60 days; subsequently, the groups were switched to the alternative regimen for the next 60 days. Reduction in BMI, HOMA-IR, cholesterol, triglycerides, liver size, and steatosis was more profound in tomato-supplemented group. Leptin decreased in both groups whereas adiponectin raised only after tomato supplementation. RCR is associated with the impaired engagement of T-cells glycolysis and proliferation, tomato-supplementation resulted in glycolytic metabolic activation of T-cells. Tomato juice ameliorates glucose and lipid metabolism in obese children, improve oxidative and inflammatory state and modulates the mitochondrial metabolism of T-cells contributing to a maintenance of a proper immune surveillance in children, impaired by RCR. The addition of tomato to RCR could be considered a protective and preventive support to obese child.</p> <p><strong>Progetto giovani ricercatori </strong>[GR-2016-02363725] dal titolo: "Immune Tolerance, Metabolism and Multiple Sclerosis: Novel Molecular Tools to Monitor Disease Pathogenesis and Progression"</p>
Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
The classical drug development pipeline necessitates studies using animal models of human disease to gauge future efficacy in humans, however there is a low conversion rate from success in animals to humans. Non-alcoholic fatty liver disease (NAFLD) is a complex chronic disease without any established therapies and a major field of animal research. We performed a meta-analysis with meta-regression of 603 interventional rodent studies (10,364 animals) in NAFLD to assess which variables influenced treatment response. Weight loss and alleviation of insulin resistance were consistently associated with improvement in NAFLD. Multiple drug classes that do not affect weight in humans caused weight loss in animals. Other study design variables, such as age of animals and dietary composition, influenced the magnitude of treatment effect. Publication bias may have increased effect estimates by 37-79%. These findings help to explain the challenge of reproducibility and translation within the field of metabolism.
Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
<p><strong>Objectives</strong>: Sarcopenia is a known risk factor for non-alcoholic fatty liver disease (NAFLD). Studies evaluating the association between the fat-to-muscle ratio (FMR) and NAFLD are limited. Therefore, the aim of our study was to investigate the association between FMR and NAFLD.</p> <p><strong>Design:</strong> A retrospective study was conducted on the individuals who underwent health examination in Wuhan Union Hospital between January 2020 and November 2021. Clinical data were collected from electronic medical records.</p> <p><strong>Setting:</strong> Our study was conducted in a hospital in China.</p> <p><strong>Participants:</strong> A total of 1,592 participants aged ≥40 years who underwent body composition analysis and liver ultrasonography were retrospectively reviewed.</p> <p><strong>Primary outcome measures:</strong> Liver ultrasonography was used to assess liver steatosis, and the Fibrosis-4 Index (FIB-4) was used to calculate the risk scores for liver fibrosis. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk prediction model was used to calculate ASCVD risk scores.</p> <p><strong>Results:</strong> The FMR was significantly higher in individuals with NAFLD than in those without NAFLD (P<0.001). The prevalence of NAFLD gradually increased from FMR tertile 1 (reference) to tertile 2 (OR=1.49, 95% CI: 1.13–1.97) and tertile 3 (OR=2.85, 95% CI: 2.08–3.90). In addition, patients with NAFLD in FMR tertile 3 had a significantly higher risk of liver fibrosis (OR=4.48, 95% CI: 2.12–9.50) and ASCVD (OR=4.63, 95% CI: 2.62–8.19) than those in FMR tertile 1 after adjustment for multiple confounders.</p> <p><strong>Conclusion:</strong> In this study, we found a significant association between FMR and NAFLD. A higher FMR indicates a higher risk of NAFLD in the study population and a higher risk of liver fibrosis and ASCVD in NAFLD patients.</p>
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
ClinicalTrials.gov study NCT00742326. IPD Sharing: NO. Countries: 1. Publications: 4.
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
ClinicalTrials.gov study NCT00063635. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
ClinicalTrials.gov study NCT01002547. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT03248882. IPD Sharing: YES. Countries: 6. Publications: 2.
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
ClinicalTrials.gov study NCT04944992. IPD Sharing: YES. Countries: 16. Publications: 1.
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
ClinicalTrials.gov study NCT04048135. IPD Sharing: UNDECIDED. Countries: 2. Publications: 3.
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT03459079. IPD Sharing: NO. Countries: 1. Publications: 10.
Insulin Resistance in Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT00252499. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.